Studied in the lab, clinically validated in humans: The science behind Neos.

(1) Neos first double-blind, randomized, placebo-controlled clinical trial, published in 26 February 2022 in the peer-reviewed journal MDPI Antioxidants (Volume 11/Issue 3): Antioxidant and Antiaging Properties of a Novel Synergistic Nutraceutical Complex: Readouts from an In Cellulo Study and an In Vivo Prospective, Randomized Trial

Cellular Senescence

Neos delays Senescence (1)

Senescent cells are former healthy cells that stopped dividing and secrete substances that damage healthy surrounding cells. Commonly referred to as “zombie cells,” these cells increase exponentially with age and lead to tissue and organ damage.

Human fibroblasts treated with Neos display an extension of replicative lifespan. By delaying senescence, Neos attenuates the age-related functional decline, maintains the regenerative capacity of tissues and organs, enhances overall wellness and promotes longevity.

Telomere Shortering

Neos prevents age-related attrition (1)

Telomeres are considered the “biological clock” of the cell, a discovery that was awarded the Nobel Prize in 2009. Telomere shortening is one of the primary causes of human aging and is associated with increased risk of age-related diseases such as cancer, heart disease, diabetes and autoimmune diseases.

Human fibroblasts treated with Neos do not exhibit telomere shortening when they reach senescence. Maintaining telomere length through Neos may have important implications for promoting Healthy Aging and preventing age-related diseases

Loss of Proteostasis

Neos increases proteasome levels (1)

As organisms age, there is a decline in Proteostasis, which plays a significant role in the aging process. This decline is primarily attributed to various cellular stresses, including oxidative stress and environmental factors that lead to protein oxidation. While Proteostasis mechanisms, including protein degradation pathways, play a crucial role in mitigating protein damage, aging is accompanied by a decline in the efficiency of the proteasome – the major cellular protein degradation system (Nobel 2004). Consequently, there is an accumulation of damaged and misfolded proteins, contributing to the development of age-related diseases such as neurodegenerative disorders, cancer, and metabolic disorders.

Neos increases Proteasome Activity.

Neos activates the proteasome and rescues its age-related deterioration in human fibroblasts.

Loss of Proteostasis

Neos decreases the levels of oxidazed proteins(1)

Neos has high anti-oxidant capacity.

Neos prevents the accumulation of oxidized proteins in “aged” human fibroblasts.  

Epigenetic Alterations

Neos preserves optimal global methylation levels (1)

During aging, the epigenome — the molecular machinery that regulates our genes’ activity — becomes disorganized. This leads to certain beneficial genes being turned off when they should be on, and genes that can cause trouble being turned on when they should be off.

The global DNA methylation levels in human fibroblasts treated with Neos throughout their lifespan are similar to those of their younger counterparts.

Resetting such epigenetic changes with Neos holds a great potential to delay the age-related functional decline.

Deregulated Nutrient Sensing

Neos activates FoxO1 (1)

During aging, our cells become less tuned to nutrient signals, which disrupts a cell’s ability to utilize and produce energy. This can result in reduced energy and metabolic dysfunction.

Neos activates FoxO1.

Human fibroblasts treated with Neos throughout their lifespan exhibit enhanced FoxO1 transcriptional activity during ageing to promote HealthSpan.


Deregulated Nutrient Sensing

Neos activates Sirt1 (1)

Neos activates Sirt1.

The Sirt1 activating properties of Neos may  provide beneficial effects such as improved metabolic health and stress response, anti-inflammatory effects, increased longevity, and protection against age-related diseases.

Clinical Trial Design

The primary outcome of the clinical study was the statistically significant decrease in oxidized plasma proteins for the volunteers that received Neos,  while for the placebo subgroup, no changes in oxidation status were observed. No harm or unintended effects were recorded. The effects were stronger in people of the age range 45-55 and in females. This decrease of oxidized protein levels is correlated to the activation of the proteasome-mediated degradation.

Clinical Effects of Neos: Enhancement of Proteostasis in vivo (1)


Reduction of Oxidized Protein Levels(1)

Neos has significant anti-oxidant effects in vivo. Neos  reduces the levels of oxidized proteins after a 3-months supplementation in healthy volunteers.


Neos increases oxidized protein degradation via the proteasome. The decline of oxidized protein levels is accompanied by an increase of proteasome activity after 3-months supplementation in healthy volunteers.